The drug development pipeline is not rigid, and is better viewed as a long flexible snake, which sometimes swallows a bowling ball, and at other times a ping pong ball. The efforts of the company and staff to pass a bowling ball through the snake will slow most of the other projects the snake has going through it.

Safety and efficacy standards can be viewed as a pair of high jumps for the product to exceed. As safer and more effective drugs reach the market, these bars become progressively raised.

Multinational clinical trials require many more resources and effort than a group of multisite uni-national trials. Is the juice worth the squeeze?

Accept your mistakes without being defensive.